Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at media@evaluate.com.
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
MarketWatch
Drug manufacturers have spent a record $342 billion on M&A in 2019
The uptick in deals underscores a broader trend in the industry, one in which large, legacy drug makers are buying their pipelines rather than developing new therapies…
Bloomberg
Miracle Cancer Drugs Are Making Big Pharma Billions. Others Are Getting Left Behind
The industry prides itself on knowing when to quit, but it’s taking a different approach with cancer treatments.
Wall Street Journal
Big Drugmakers Push Deeper Into Cancer Treatment
The $123 billion world-wide cancer-drugs market is expected to almost double by 2024, according to a market-research firm, EvaluatePharma.
The Pharma Letter
News review for the week ending December 6
Sales of AT132 will reach $38.1 million in 2024, according to EvaluatePharma's sell-side consensus, though this figure will be highly risk adjusted.
PMLive
Lynparza cleared for first-line ovarian cancer use in China
EvaluatePharma has projected that the Lynparza will continue to grow to produce annual revenues of $2.2bn by 2024.
The Pharma Letter
Lexicon shares dented by fresh FDA rebuke
Consensus forecasts from EvaluatePharma suggest Zynquista, if it gains approval, could have sales of $1.16 billion by 2022.
Pharmaphorum
NICE backs Ibrance for breast cancer via Cancer Drugs Fund
EvaluatePharma analysts have previously predicted it could go as high as $6 billion in 2022, staying ahead of its rivals with Novartis and Lilly’s drugs jostling for…
Wall Street Journal
Novartis to Buy Cholesterol-Drugmaker Medicines Co.
World-wide sales of cholesterol drugs are growing nearly 11% a year and are projected to reach $17.7 billion in 2024, according to EvaluatePharma.
FiercePharma
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Approved by the FDA in late March for the treatment of relapsing forms of MS, including active secondary progressive MS and relapsing remitting MS, Mayzent’s potential…
PMLive
Biogen under fire over $88,000 Vumerity annual price
Consensus estimates compiled by EvaluatePharma reflect this with forecast sales of Vumerity at a modest $111m in 2024.
